Status:
RECRUITING
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
Lead Sponsor:
Astellas Pharma Korea, Inc.
Conditions:
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Eligibility:
All Genders
Brief Summary
This study is for people in South Korea who have cancer in or around the stomach (gastric cancer) or cancer where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) ca...
Eligibility Criteria
Inclusion
- Patients who receive treatment with VYLOY injection, according to the approved local label.
Exclusion
- Patients with any contraindication for VYLOY injection, according to the approved local label.
- Patients who are registered or scheduled to be registered in any clinical trials involving investigational drug administration.
Key Trial Info
Start Date :
April 3 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2030
Estimated Enrollment :
377 Patients enrolled
Trial Details
Trial ID
NCT06902545
Start Date
April 3 2025
End Date
July 31 2030
Last Update
December 16 2025
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
KR82010
Goyang-si, Gyeonggi-do, South Korea
2
KR82008
Suwon, Gyeonggi-do, South Korea
3
KR82006
Yangsan, Gyeongsangnam-do, South Korea
4
KR82012
Hwasun Gun, Jeollanam-do, South Korea